Ionis Pharmaceuticals, Inc.

NasdaqGS:IONS Stock Report

Market Cap: US$13.1b

Ionis Pharmaceuticals Management

Management criteria checks 3/4

Ionis Pharmaceuticals' CEO is Brett Monia, appointed in Jan 2020, has a tenure of 6.17 years. total yearly compensation is $15.40M, comprised of 6.6% salary and 93.4% bonuses, including company stock and options. directly owns 0.15% of the company’s shares, worth $20.22M. The average tenure of the management team and the board of directors is 6.1 years and 9.8 years respectively.

Key information

Brett Monia

Chief executive officer

US$15.4m

Total compensation

CEO salary percentage6.55%
CEO tenure6.2yrs
CEO ownership0.2%
Management average tenure6.1yrs
Board average tenure9.8yrs

Recent management updates

Recent updates

Ionis Pharmaceuticals: Digesting Recent Events

Feb 27

Earnings Update: Here's Why Analysts Just Lifted Their Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Price Target To US$81.91

Nov 01
Earnings Update: Here's Why Analysts Just Lifted Their Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Price Target To US$81.91

Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) 34% Share Price Surge Not Quite Adding Up

Sep 03
Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) 34% Share Price Surge Not Quite Adding Up

Analysts Just Published A Bright New Outlook For Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS)

Aug 01
Analysts Just Published A Bright New Outlook For Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS)

Is Ionis Pharmaceuticals (NASDAQ:IONS) Using Too Much Debt?

Jul 30
Is Ionis Pharmaceuticals (NASDAQ:IONS) Using Too Much Debt?

Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) Shares Climb 28% But Its Business Is Yet to Catch Up

Jul 03
Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) Shares Climb 28% But Its Business Is Yet to Catch Up

We Discuss Why Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) CEO Compensation May Be Closely Reviewed

May 30
We Discuss Why Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) CEO Compensation May Be Closely Reviewed

Analysts Just Shipped A Substantial Upgrade To Their Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Estimates

May 02
Analysts Just Shipped A Substantial Upgrade To Their Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Estimates

Ionis: Potentially A Great Time To Buy Ahead Of Q1 Earnings (Upgrade)

Apr 22

Is Ionis Pharmaceuticals (NASDAQ:IONS) Using Debt In A Risky Way?

Apr 20
Is Ionis Pharmaceuticals (NASDAQ:IONS) Using Debt In A Risky Way?

Lacklustre Performance Is Driving Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) Low P/S

Mar 24
Lacklustre Performance Is Driving Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) Low P/S
User avatar

Anticipated Drug Launches Will Shift Biotech Company To Commercial Stage

Ionis is set to boost revenue through first-mover advantage with TRYNGOLZA and other product launches targeting unmet medical needs.

Ionis Pharmaceuticals: Promising Growth From Tryngolza Approval

Dec 23

Ionis Pharmaceuticals: Catalysts Due In 2025/2026 Are Extremely Compelling

Oct 23

Ionis Pharmaceuticals: Harnessing RNA-Targeted Therapies For Long-Term Shareholder Value

Aug 11

CEO Compensation Analysis

How has Brett Monia's remuneration changed compared to Ionis Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2025n/an/a

-US$381m

Sep 30 2025n/an/a

-US$256m

Jun 30 2025n/an/a

-US$268m

Mar 31 2025n/an/a

-US$458m

Dec 31 2024US$15mUS$1m

-US$454m

Sep 30 2024n/an/a

-US$359m

Jun 30 2024n/an/a

-US$366m

Mar 31 2024n/an/a

-US$385m

Dec 31 2023US$13mUS$961k

-US$366m

Sep 30 2023n/an/a

-US$409m

Jun 30 2023n/an/a

-US$309m

Mar 31 2023n/an/a

-US$329m

Dec 31 2022US$7mUS$825k

-US$270m

Sep 30 2022n/an/a

US$7m

Jun 30 2022n/an/a

-US$28m

Mar 31 2022n/an/a

-US$4m

Dec 31 2021US$13mUS$800k

-US$29m

Sep 30 2021n/an/a

-US$608m

Jun 30 2021n/an/a

-US$550m

Mar 31 2021n/an/a

-US$495m

Dec 31 2020US$11mUS$700k

-US$444m

Sep 30 2020n/an/a

US$94m

Jun 30 2020n/an/a

US$145m

Mar 31 2020n/an/a

US$169m

Dec 31 2019US$7mUS$528k

US$281m

Compensation vs Market: Brett's total compensation ($USD15.40M) is about average for companies of similar size in the US market ($USD13.43M).

Compensation vs Earnings: Brett's compensation has increased whilst the company is unprofitable.

CEO

Brett Monia (64 yo)

6.2yrs
Tenure
US$15,400,343
Compensation

Dr. Brett P. Monia, Ph.D. is a Founder of Ionis Pharmaceuticals, Inc. in 1989 and has been Chief Executive Officer since January 2020. He has extensive experience across a range of therapeutic areas, inclu...

Leadership Team

NamePositionTenureCompensationOwnership
Brett Monia
Founder6.2yrsUS$15.40m0.15%
$ 20.2m
Elizabeth Hougen
Executive VP of Finance & CFO13.2yrsUS$5.06m0.080%
$ 10.6m
Patrick O'Neil
Executive VP13.2yrsUS$3.43m0.044%
$ 5.7m
Kyle Jenne
Executive VP & Chief Global Product Strategy Officer2.2yrsUS$4.30m0.0099%
$ 1.3m
Richard Geary
Strategic Consultantless than a yearUS$3.47m0.036%
$ 4.7m
Eugene Schneider
Executive VP2.5yrsno data0.042%
$ 5.5m
Darren Gonzales
Chief Accounting Officer & Senior VP6.1yrsno datano data
C. Bennett
Executive VP & Chief Scientific Officer6.2yrsUS$958.87k0.061%
$ 8.0m
D. Walke
Senior Vice President of Investor Relationsno datano datano data
Tracy Berns
Senior VP and Chief Compliance & Quality Assurance Officerno datano datano data
Hayley Soffer
Vice President of Corporate Communications2.2yrsno datano data
Shannon L. Devers
Executive VP & Chief Human Resource Officer6.1yrsno data0.014%
$ 1.8m
6.1yrs
Average Tenure
58yo
Average Age

Experienced Management: IONS's management team is seasoned and experienced (6.1 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Brett Monia
Founder7yrsUS$15.40m0.15%
$ 20.2m
B. Parshall
Director25.5yrsUS$559.93k0.034%
$ 4.5m
Joan Herman
Independent Director6.8yrsUS$561.93k0.028%
$ 3.7m
Joseph Klein
Independent Director20.3yrsUS$563.93k0.010%
$ 1.3m
Joseph Wender
Lead Independent Director32.2yrsUS$619.93k0.032%
$ 4.1m
Michael Hayden
Independent Director7.5yrsUS$549.93k0.034%
$ 4.5m
Spencer Berthelsen
Independent Director23.8yrsUS$569.93k0.094%
$ 12.4m
Joseph Loscalzo
Independent Chairman of the Board12.1yrsUS$589.93k0.022%
$ 2.9m
Allene Diaz
Independent Director4.8yrsUS$551.93k0.011%
$ 1.5m
Michael Yang
Independent Director2.3yrsUS$849.98k0.0048%
$ 631.3k
9.8yrs
Average Tenure
71yo
Average Age

Experienced Board: IONS's board of directors are considered experienced (9.8 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/03/05 15:58
End of Day Share Price 2026/03/05 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Ionis Pharmaceuticals, Inc. is covered by 42 analysts. 19 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
James BirchenoughBarclays
Eliana MerleBarclays
Huidong WangBarclays